Proteina Co., Ltd.

₩58,800As of Sun 8 Nov 2026, 12:00 UTC

KOSDAQ:468530Healthcare

Country South Korea

PE (Fwd) —

TSR 10Y CAGR —

Div yield —

ROE (52.88%)

Biotechnology

Beta (5Y) —

PE TTM —

TSR TTM (7.26%)

Mkt cap ₩653.0B

ROIC (75.31%)

SE Grade™

—

Value

Quality

Moat

1Y Price

Reference

₩62,610

6.48%

(97.58%)

Price above Reference Value

TTM

FYE 31 Dec KRW

FY2021

FY2022

FY2023

FY2024

FY2025

FY2026E

Trend

10Y

Peers

1.443

Revenue₩B

—

0.466

0.578

2.301

2.951

3.824

85.06%

—

Revenue growth%

—

24.16

297.96

28.26

29.59

28.26

—

42.91

Gross margin%

—

100.00

87.03

63.58

52.17

42.57

75.31

—

(1112.94)

Operating margin%

—

(1155.26)

(1255.07)

(396.45)

(385.23)

(100.00)

(775.86)

—

(831.41)

Net margin%

—

(2442.03)

(3941.31)

(249.23)

(305.39)

(100.00)

(1373.71)

—

P/E ratio (avg)x

—

EV/EBITx

—

(1.88)

FCF yield (avg)%

—

(1.83)

(0.65)

(1.83)

—

(842.21)

FCF margin%

—

(996.69)

(1033.70)

(364.98)

(324.69)

(100.00)

(680.83)

—

1.013

FCF / Net incomex

—

0.408

0.262

1.464

1.063

—

0.736

—

(75.31)

ROIC%

—

(89.54)

(17.93)

(89.54)

—

(52.88)

Return on equity%

—

(40.84)

(17.60)

(40.84)

—

(45.35)

Return on assets%

—

(85.36)

(94.90)

(31.91)

(28.38)

(15.59)

(58.63)

—

(1,091)

EPS₩

—

(13,418)

(5,378)

(1,035)

(906.00)

(384.46)

—

EPS growth%

—

59.92

80.75

12.46

57.57

59.92

—

2,064

Bookvalue per sh₩

—

(35,896)

(12,390)

2,844

2,853

2,088

0.29%

—

(1,105)

FCF per share₩

—

(5,476)

(1,411)

(1,516)

(963.23)

(384.46)

—

Dividend per sh₩

—

Div yield (avg)%

—

Payout ratio%

—

11.11

Shares (diluted)M

—

0.847

4.237

5.540

9.947

◌9.947

127.26%

—

Buyback yield%

—

(399.98)

(30.76)

(79.54)

◌—

(79.54)

—

0.032

D/E ratiox

—

(0.013)

—

0.064

0.031

0.035

0.013

—

644.9

Enterprise value₩B

—

515.7

585.4

—

LT debt₩M

—

Peers (US$447.5M)

Cap (US$)

Chabiotech Co.,Ltd.

497.2M

623.0x

Komipharm Internationa…

453.1M

—

Hyundai Bioscience Co.…

401.3M

—

Qingdao Vland Biotech…

449.8M

40.96x

Capital

TTM

10Y

Leveragex

—

EBIT/Intx

(155.5)

(2.808)

Own earn%

—

Sh yield%

—

(79.54)

Owners

Insiders/Inst%

23.48

27.80

Short interest%

—

SBC / revenue%

—

Record

10Y

Profitable years

0/4

Revenue growth years

3/3

EPS growth years

3/3

Dividend streakyrs

Op margin range%

−1255–−385

$1 testx

—

Incr. ROIC%

—

Proteina Co., Ltd. develops protein-protein interaction profiling technology. The company offers technology that confirms the real-time activation of cancer signal pathways by directly seeing the relevant proteins, predicts the efficacy of drugs, and enables doctors to select which inhibitor to prescribe by confirming which bypass signal pathways are inducing resistance.

Growth vs revenue

Latest

Trend

3Y CAGR

Rel growth

Revenue

₩2.951B

85.06%

1.00×

Cost of revenue

₩1.411B

Operating expenses

₩12.91B

30.22%

0.35×

Asset mix

Trend

Other

70.59%

Cash and investments

27.68%

Goodwill & intangibles

1.73%

Reinvestment returns

No breakdown available